Pembrolizumab for Recurrent Conjunctival Melanoma

JAMA Ophthalmol. 2017 Aug 1;135(8):891-892. doi: 10.1001/jamaophthalmol.2017.2279.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Conjunctival Neoplasms / diagnostic imaging
  • Conjunctival Neoplasms / drug therapy*
  • Conjunctival Neoplasms / pathology
  • Humans
  • Injections, Intravenous
  • Male
  • Melanoma / diagnostic imaging
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Programmed Cell Death 1 Receptor

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor
  • pembrolizumab